Policy pathways and historical insights: Canada's evolving approach to psychedelic access for end-of-life distress

Canada's evolving approach to psychedelic interventions in palliative and end-of-life care marks a departure from historically prohibitionist policies, recognizing their therapeutic potential for end-of-life distress. This shift parallels international regulatory developments in the United States, Australia, and parts of Europe, where cautious policy liberalization signals growing clinical acceptance. Canada's formative role in modern palliative care, its holistic frameworks for end-of-life suffering, and experience with medical assistance in dying shape national conversations about suffering and autonomy. Federal flexibility, compassionate access mechanisms, and patient advocacy, combined with rising public demand and incremental provincial changes, position Canada along a transitional pathway toward clinical integration, though drug policy remains heterogeneous across substances and provinces.

Study at a glance

Abstract

Canada's evolving attitudes toward psychedelic interventions in palliative and end-of-life care reflect a departure from historically prohibitionist policies and an emerging recognition of their therapeutic potential for individuals facing end-of-life distress. This shift parallels international regulatory developments in jurisdictions such as the United States, Australia and parts of Europe, where cautious policy liberalization has signaled growing acceptance of psychedelics within clinical contexts. Canada is also a relevant case because of its formative role in the development of modern palliative care, its contemporary frameworks emphasizing holistic approaches to suffering at the end of life, and its experience with medical assistance in dying, all of which have shaped national conversations about suffering, autonomy, and end-of-life care. Additionally, Canada's distinctive historical approach to drug regulation-marked by federal flexibility, mechanisms for compassionate access, and responsiveness to patient advocacy-combined with rising public demand and incremental provincial changes, may uniquely position the country along a transitional pathway toward clinical integration of psychedelics in palliative care. At the same time, Canadian drug policy remains heterogeneous across substances and provinces, underscoring the political contingency of reform. Within this dynamic landscape, Canada's psychedelic drug policy trajectory aligns with broader international trends toward cautious medicalization and regulated access to psychedelic therapies, while also offering an instructive case for how end-of-life frameworks and federal-provincial governance shape policy development.